Curing blindness through regenerative cell therapies. We replace what is lost.

StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness. ​

We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.

<p><span>The most innovative startup in health and life sciences in Europe at BioFit, 2020</span></p>

The most innovative startup in health and life sciences in Europe at BioFit, 2020

Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023

About us

The founding team of StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications. The scientific excellence is complemented by our distinguished board of accomplished industry leaders and advisors with extensive global business acumen.
READ MORE

Latest News

2026-04-13 00:00:00

StemSight speaking at BioTrinity 2026

CEO Laura Koivusalo will attend BioTrinity 2026 in London on April 14-15, where she will present StemSight's pioneering work in the Series A R&D Presentations (Session 3). See the full programme here.

2026-03-24 00:00:00

StemSight at the SOT 65th Annual Meeting

StemSight attends the SOT 65th Annual Meeting in San Diego on March 22-25, 2026. Our CSO Tanja Ilmarinen will be presenting on March 25, 2026, in the special symposium Visionary Foresight: Pioneering Cell-Based Therapies.

 

2026-04-13 00:00:00

New CheckOrphan article featuring StemSight

Our Chief Commercial Officer Ross Macdonald shares insights in a recent CheckOrphan interview on how StemSight's technology aims to cure limbal stem cell deficiency. Read the full piece to learn more about the future of regenerative eye therapies.

2026-03-24 00:00:00

StemSight attending BIO Europe and LSX in Lisbon

Our Chief Commercial Officer Ross Macdonald is attending both BIO Europe and LSX in Lisbon on March 23–25, 2026. We invite fellow attendees to engage with us regarding partnership opportunities and to gain further insight into our upcoming Series A.

 

 
More News

Want to know more?

Interested to join our next investment round? Want to hear about our latest developments? Just thought of someone we absolutely need to meet?

Send us a message!

CONTACT US

Subscribe to our newsletter

Subscribe now

Supported by:

Co-funded by: